$DGX News

Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236

Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?

Quest Diagnostics's Q2 2026 Earnings: What to Expect

Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry

Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs

DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Quest Diagnostics Receives New York's Department of Health's Clinical Laboratory Evaluation Program Approval For Its Haystack Minimal Residual Disease Liquid Biopsy Test To Trace Residual Or Recurring Disease In Solid Tumor Cancers Patients

Is Quest Diagnostics Stock Underperforming the S&P 500?

UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics

Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026

Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report

Quest Diagnostics Inc (NYSE:DGX): A Top Dividend Stock with Sustainable Income and Growth Potential

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare

How The Quest Diagnostics (DGX) Investment Story Is Evolving Without New Analyst Price Target Changes

Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know

3 Reasons to Sell DGX and 1 Stock to Buy Instead